The European Patent Office (EPO) has granted patent EP3714048B1, titled "POLYNUCLEOTIDES ENCODING ORNITHINE TRANSCARBAMYLASE FOR THE TREATMENT OF UREA CYCLE DISORDERS." The patent was officially granted on March 18, 2026, and lists several inventors. This grant signifies the EPO's recognition of novel polynucleotide technology for treating urea cycle disorders.

This is a patent grant, not a regulatory rule with compliance obligations for companies. It primarily impacts intellectual property strategy for pharmaceutical and biotechnology firms involved in gene therapy or the treatment of metabolic disorders. Companies operating in this space should be aware of this granted patent as it may affect their freedom to operate or potential licensing opportunities within the designated European states.